Quoin Pharmaceuticals (QNRX) Cash from Financing Activities (2021 - 2026)
Quoin Pharmaceuticals (QNRX) posted Cash from Financing Activities of $55982.0 for Q1 2026, down 99.69% sequentially from $18.3 million in Q4 2025, and up 143.85% YoY from $22958.0 in Q1 2025.
Quoin Pharmaceuticals (QNRX) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Quoin Pharmaceuticals has reported Cash from Financing Activities for 6 years, with the latest figure at $55982.0 in Q1 2026.
- Quarterly Cash from Financing Activities rose 143.85% year-over-year to $55982.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.0 million (up 218.95% YoY) and the FY2025 annual result came in at $18.0 million, up 64.25% from the prior year.
- Cash from Financing Activities retreated to $55982.0 in Q1 2026 per QNRX's latest filing, from $18.3 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $18.3 million in Q4 2025 and troughed at -$446862.0 in Q4 2022.
- A 5-year average of $2.8 million and a median of -$136275.0 in 2024 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 28060.15% in 2022, down 104.36% in 2022.
- Over 5 years, Cash from Financing Activities stood at -$446862.0 in 2022, then jumped by 59.14% to -$182583.0 in 2023, then surged by 3343.14% to $5.9 million in 2024, then surged by 208.9% to $18.3 million in 2025, then sank by 99.69% to $55982.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $55982.0, $18.3 million, and -$150000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Quoin Pharmaceuticals | 531,643.73 | 531,643.73 | - | -151,947.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55,982.00 |
| Mar 31, 2026 | 55,982.00 |
| Dec 31, 2025 | 18.29 Mn |
| Dec 31, 2025 | 18.29 Mn |
| Sep 30, 2025 | -150,000.00 |
| Sep 30, 2025 | -150,000.00 |
| Jun 30, 2025 | -150,000.00 |
| Jun 30, 2025 | -150,000.00 |
| Mar 31, 2025 | 22,958.00 |
| Mar 31, 2025 | 22,958.00 |
| Dec 31, 2024 | 5.92 Mn |
| Dec 31, 2024 | 5.92 Mn |
| Sep 30, 2024 | -149,892.00 |
| Sep 30, 2024 | -149,892.00 |
| Jun 30, 2024 | -136,275.00 |
| Jun 30, 2024 | -136,275.00 |
| Mar 31, 2024 | 5.33 Mn |
| Mar 31, 2024 | 5.33 Mn |
| Dec 31, 2023 | -182,583.00 |
| Dec 31, 2023 | -182,583.00 |